TrialEuropean urology oncology2025

Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial.

Ryan M Phillips et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.